GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Financial Strength

BioDelivery Sciences International (FRA:BD5) Financial Strength : 7 (As of Dec. 2021)


View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Financial Strength?

BioDelivery Sciences International has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

BioDelivery Sciences International's Interest Coverage for the quarter that ended in Dec. 2021 was 5.90. BioDelivery Sciences International's debt to revenue ratio for the quarter that ended in Dec. 2021 was 0.34. As of today, BioDelivery Sciences International's Altman Z-Score is 2.76.


Competitive Comparison of BioDelivery Sciences International's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's Financial Strength distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's Financial Strength falls into.



BioDelivery Sciences International Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

BioDelivery Sciences International's Interest Expense for the months ended in Dec. 2021 was €-1.4 Mil. Its Operating Income for the months ended in Dec. 2021 was €8.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was €47.9 Mil.

BioDelivery Sciences International's Interest Coverage for the quarter that ended in Dec. 2021 is

Interest Coverage=-1*Operating Income (Q: Dec. 2021 )/Interest Expense (Q: Dec. 2021 )
=-1*8.011/-1.358
=5.90

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

BioDelivery Sciences International's Debt to Revenue Ratio for the quarter that ended in Dec. 2021 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2021 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.084 + 47.947) / 152.764
=0.34

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

BioDelivery Sciences International has a Z-score of 2.76, indicating it is in Grey Zones. This implies that BioDelivery Sciences International is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.76 is in grey area. The implies that the company is in some kind of financial stress. If it is below 1.8, the company may faces bankrupcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioDelivery Sciences International  (FRA:BD5) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

BioDelivery Sciences International has the Financial Strength Rank of 7.


BioDelivery Sciences International Financial Strength Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (FRA:BD5) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines